Seek Returns

A vs. BBIO: Agilent vs. BridgeBio Pharma Stock Comparison

How do Agilent (A) and BridgeBio Pharma (BBIO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and BridgeBio Pharma (BBIO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while BBIO is classified in Biotechnology.

Company profile comparison for Agilent (A) and BridgeBio Pharma (BBIO)
Profile ItemABBIO
NameAgileThought, Inc. Class A Common StockBridgeBio Pharma Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization49.28 billion USD14.47 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateNovember 18, 1999June 27, 2019
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

A
BBIO
GSPC
Loading price history…
Agilent (A) vs. BridgeBio Pharma (BBIO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Agilent (A) and BridgeBio Pharma (BBIO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Agilent (A) and BridgeBio Pharma (BBIO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and BridgeBio Pharma (BBIO)
MetricABBIO
Total Return (1Y)22.92%22.70%
Total Return (3Y, Annualized)19.33%40.97%
Total Return (5Y, Annualized)3.03%8.25%

Risk Profile

Drawdown History

A
BBIO
GSPC
Loading price history…
Agilent (A) vs. BridgeBio Pharma (BBIO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Agilent (A) and BridgeBio Pharma (BBIO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and BridgeBio Pharma (BBIO)
MetricABBIO
Volatility (1Y, Annualized)33.10%44.39%
Beta (5Y)1.220.93
Max Drawdown (5Y)-38.09%-89.79%
Avg. Volume (3M)2.25M2.68M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
A and BBIO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and BridgeBio Pharma (BBIO)
MetricABBIO
Sharpe Ratio (1Y)0.560.41
Sortino Ratio (1Y)0.960.63

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Agilent (A) earns 20.97% on shareholders’ equity, ranked against its industry; BridgeBio Pharma (BBIO) has no ROE this period.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max
109.18%
A
20.97%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
BBIO
--
Loading chart…
Agilent (A) vs. BridgeBio Pharma (BBIO): BBIO does not report ROE, so it has no value marker; A is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Agilent (A) reports 19.53%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A
19.53%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-59.84%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
BBIO
-59.84%
Loading chart…
Agilent (A) vs. BridgeBio Pharma (BBIO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Agilent (A) reports 25.56%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max
83.12%
A
25.56%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-3.30%

Max
83.12%
Q3
14.77%
Median
0.00%
BBIO
-3.30%
Q1
-78.82%
Min
-207.40%
Loading chart…
Agilent (A) vs. BridgeBio Pharma (BBIO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and BridgeBio Pharma (BBIO)
MetricABBIO
ROE (TTM)20.97%--
ROA (TTM)8.63%-13.97%
Net Margin (TTM)19.53%-59.84%
Operating Margin (TTM)25.56%-3.30%
Gross Margin (TTM)53.65%94.34%

Growth

Revenue Growth

BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while Agilent (A) at 6.73% is closer to the peer norm — faster top-line expansion for BBIO.

Loading chart…
Agilent (A) vs. BridgeBio Pharma (BBIO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Agilent (A) reports EPS growth of 3.16%, ranked against its industry; BridgeBio Pharma (BBIO) has no EPS growth figure this period.

Loading chart…
Agilent (A) vs. BridgeBio Pharma (BBIO): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and BridgeBio Pharma (BBIO)
MetricABBIO
Revenue Growth (YoY)6.73%126.26%
Revenue Growth (3Y CAGR)0.48%86.30%
EPS Growth (YoY)3.16%--
EPS Growth (3Y CAGR)3.02%--

Financial Strength

Current Ratio (MRQ)

Both Agilent (A) at 2.05 and BridgeBio Pharma (BBIO) at 2.09 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
A
2.05
Min
0.10

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.09

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BBIO
2.09
Min
0.10
Loading chart…
Agilent (A) vs. BridgeBio Pharma (BBIO): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Agilent (A) carries debt-to-equity ratio of 0.56 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max
1.42
Q3
0.65
A
0.56
Median
0.15
Q1
0.02
Min
0.00

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
BBIO
--
Loading chart…
Agilent (A) vs. BridgeBio Pharma (BBIO): BBIO does not report debt-to-equity ratio, so it has no value marker; A is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and BridgeBio Pharma (BBIO)
MetricABBIO
Current Ratio (MRQ)2.052.09
Debt / Equity (MRQ)0.56--
Net Debt / EBITDA1.15--

Dividends

Dividend Yield (TTM)

BridgeBio Pharma (BBIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A
0.59%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. BridgeBio Pharma (BBIO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

BridgeBio Pharma (BBIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A
19.98%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. BridgeBio Pharma (BBIO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and BridgeBio Pharma (BBIO)
MetricABBIO
Dividend Yield (TTM)0.59%0.00%
Dividend Payout Ratio (TTM)19.98%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Agilent (A) trades at 34.47 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max
85.34
Q3
43.46
A
34.47
Median
26.69
Q1
13.30
Min
0.07

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BBIO
--
Loading chart…
Agilent (A) vs. BridgeBio Pharma (BBIO): BBIO does not report P/E ratio, so it has no value marker; A is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Agilent (A) at 6.68 and BridgeBio Pharma (BBIO) at 15.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
A
6.68
Q1
3.01
Min
0.01

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.31

Max
58.18
Q3
25.77
BBIO
15.31
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Agilent (A) vs. BridgeBio Pharma (BBIO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Agilent (A) reports 6.69, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max
13.53
A
6.69
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-5.59

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BBIO
-5.59
Min
-5.59
Loading chart…
Agilent (A) vs. BridgeBio Pharma (BBIO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and BridgeBio Pharma (BBIO)
MetricABBIO
P/E Ratio (TTM)34.47--
P/S Ratio (TTM)6.6815.31
P/B Ratio (MRQ)6.69-5.59
Free Cash Flow Yield (TTM)2.15%-1.98%